CDISC – 17/12/2012

Carine Javierre

Nathalie SABIN

AGENDA

1- CDISC organizational structure

2- Strategic Alliances

3- Overview of new regulatory procedure

4- Impacts on CDISC standards

CDISC organizational structure

CDISC – 17/12/2012

CDISC organizational structure

• 1990: The International Conference on Harmonisation (ICH),

• Problem: need to internationalize the pharmaceutical market between the three areas :

Europe (EMA), Japan (MHLW), United States (FDA)

Need to establish a common procedure for the registration of a new drug

CDISC – 17/12/2012

CDISC organizational structure• Founded 1997, incorporated 2000• Members of the organisation :

Pharmaceutical laboratories Regulatory Agencies CRO…

CDISC is a global, open, multidisciplinary, non-profit organization that has established standards to

support : “Clinical Data Acquisition”, “Clinical Data Exchange”, “Clinical Data Submission”, And “Clinical Data Archiving”.

CDISC – 17/12/2012

CDISC organizational structure

CDISC – 17/12/2012

CDISC Around the Globe

7

20002008 2002

2001

2010

CDISC – 17/12/2012

Strategic Alliances

CDISC – 17/12/2012

BRIDG Model 3.0.3

Day 3 Advanced - 9

The goal of the BRIDG Model is to produce a shared view of the dynamic and static semantics for the domain of protocol-driven research and its associated regulatory artifacts

What is the relationship between CDISC and Health Level Seven (HL7)?

• CDISC has an Associate Charter Agreement with HL7 that was originally signed in 2001, renewed approximately every two years. – The Charter Agreement encourages a relationship that focuses on

harmonization of the CDISC clinical research standards and the HL7 healthcare standards. 

– To this end, BRIDG was initiated in 2004 and is now a collaborative model (www.bridgmodel.org) governed by a Board comprised of CDISC, HL7, NCI (National Cancer Institute), NIH (National Intitutes of Health) and FDA.

CDISC – 17/12/2012

• The CDISC President and CEO, Rebecca Kush, was elected to the HL7 Board of Directors.  The current HL7 CEO served 6 years on the CDISC Board before taking his HL7 CEO position.  These relationships can facilitate understanding in terms of the importance and need to link healthcare and research through standards.

What is the relationship between CDISC and FDA?

   

• FDA's official position is that of "observer" when involved in CDISC activities.

• FDA representatives participate as liaisons on CDISC teams, present at CDISC conferences, present at other industry conference on the need for (CDISC) standards. FDA presentations have provided public endorsement of CDISC activities, including encouragement to those developing eSubmissions to use SDTM and ADaM.

• CDISC was awarded a contract from FDA to teaching reviewers and statisticians about CDISC; through this relationship, there are four different CDISC courses, including SDTM and ADaM, which have been taught now to over 300 reviewers. 

CDISC – 17/12/2012

Overview of new regulatory procedure

CDISC – 17/12/2012

CDISC – 17/12/2012

PDUFA REAUTHORIZATION PERFORMANCE GOALS AND PROCEDURES FISCAL YEARS 2013 THROUGH 2017

XII. IMPROVING THE EFFICIENCY OF HUMAN DRUG REVIEW THROUGH REQUIRED ELECTRONIC SUBMISSIONS AND STANDARDIZATION OF ELECTRONIC DRUG APPLICATION DATA

E. Clinical Terminology Standards: Using a public process that allows for stakeholder input, FDA shall develop standardized clinical data terminology through open standards development organizations (i.e., the Clinical Data Interchange Standards Consortium (CDISC)) with the goal of completing clinical data terminology and detailed implementation guides by FY 2017.1. FDA shall develop a project plan for distinct therapeutic indications,

prioritizing clinical terminology standards development within and across review divisions. FDA shall publish a proposed project plan for

stakeholder review and comment by June 30, 2013. FDA shall update and publish itsproject plan annually.

Impacts on CDISC standards

CDISC – 17/12/2012

CDER/CBER’s - Background

• ~ 30% of unique New Drug Applications (NDA) received by CDER in 2011 submitted CDISC/SDTM data

• ~ 20% of the Biological License Applications (BLA) received by CBER in 2011 submitted CDISC/SDTM data

• Although standardization has allowed for use of additional data analysis tools, issues with either the implementation of the standard, or the standard itself, have proven to be inhibitive to the regulatory review process

The Center for Biologics Evaluation and Research (CBER) is one of six main centers for the U.S. Food and Drug Administration (FDA), which is a part of the U.S. Department of Health and Human Services.

The Center for Drug Evaluation and Research (CDER, pronounced "see'-der") is a division of the U.S. Food and Drug Administration (FDA) that monitors most drugs as defined in the Food, Drug, and Cosmetic Act.

CDISC – 17/12/2012

Top 7 CDISC Standards Issues

• 1 - Waste of Space• 2 - Extras• 3 - Validation Errors• 4 - Extended Codelists• 5 - ISO Dates• 6 - Traceability• 7 - Inadequate Documentation

CDISC – 17/12/2012

What is the FDA looking for…?

CDISC – 17/12/2012

Q&A

Thank you

CDISC – 17/12/2012